Patents Examined by Ileana Popa
  • Patent number: 10301594
    Abstract: Compositions comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions therewith.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: May 28, 2019
    Assignee: RUBIUS THERAPEUTICS, INC
    Inventors: Avak Kahvejian, Jordi Mata-Fink, John Round, David Arthur Berry, Noubar B. Afeyan
  • Patent number: 10260045
    Abstract: This invention provides methods of inducing and maintaining osteogenic potential in mesenchymal stem cells and compositions for doing the same. The compositions this invention comprise collagen 7 (C7), the NC1 domain of C7, or the 27 kD fragment of C7. Also provided are methods for treating bone diseases and correcting bone defects by applying compositions of this invention or by first priming ex vivo mesenchymal stem cells with compositions of this invention and then applying the primed mesenchymal stem cells to the patient. The invention further provides a mesenchymal stem cell osteogenesis induction kit.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: April 16, 2019
    Assignee: University of Southern California
    Inventors: Mei Chen, David Woodley
  • Patent number: 10253296
    Abstract: Compositions comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions therewith.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: April 9, 2019
    Assignee: RUBIUS THERAPEUTICS, INC.
    Inventors: Avak Kahvejian, Jordi Mata-Fink, John Round, David Arthur Berry, Noubar B. Afeyan
  • Patent number: 10233421
    Abstract: The present invention is directed to methods to differentiate pluripotent stem cells. In particular, the present invention is directed to methods and compositions to differentiate pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage comprising culturing the pluripotent stem cells in medium comprising a sufficient amount of GDF-8 to cause the differentiation of the pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: March 19, 2019
    Assignee: Janssen Biotech, Inc.
    Inventors: Janet Davis, Jiajian Liu, Christine Parmenter, Pascal Ghislain Andre Bonnet
  • Patent number: 10220082
    Abstract: Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a mutated WT1 antigen. Vectors, compositions and vaccines comprising one or more nucleic acid sequences that encode a mutated WT1 antigen are disclosed. Methods of treating an individual who has a WT1-expressing tumor and methods of preventing a WT1-expressing tumor are disclosed. Mutated WT1 antigen is disclosed.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: March 5, 2019
    Assignees: INOVIO PHARMACEUTICALS, INC., THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: David B. Weiner, Jian Yan, Jewell Walters
  • Patent number: 10208086
    Abstract: Compositions and methods are provided for eliciting antigen-specific T-cell responses against human cyclin A1 (CCNA1), which is herein identified as a leukemia-associated antigen based on its overexpression in acute myeloid leukemia (AML) including leukemia stem cells (LSC) and in immunologically privileged testis cells, but not in other normal cell types. CCNA1-derived peptide epitopes that are immunogenic for T-cells including CTL are disclosed, as are immunotherapeutic approaches using such peptides for vaccines and generation of adoptive transfer therapeutic cells.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: February 19, 2019
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Philip Greenberg, Sebastian Ochsenreither
  • Patent number: 10184943
    Abstract: The present invention relates to a biomarker set for diagnosing breast cancer comprising two or more protein markers of: apolipoprotein C1, apolipoprotein (a), neural cell adhesion molecule L1-like protein, carbonic anhydrase 1, and fibronectin; a method for detecting the biomarker set in a blood sample through a multiple reaction monitoring; a kit for diagnosing breast cancer comprising antibodies specific to each of the proteins of the biomarker set; and a method for detecting proteins of the marker set in a blood sample through an antigen-antibody binding reaction. The method for detecting the protein marker set in a blood sample by the MRM method or antigen-antibody binding reaction and the diagnostic kit can provide very high accuracy and sensitivity in comparison with the diagnosis method using a single marker and can very conveniently diagnose breast cancer using blood from patients, thereby being effectively used for early diagnosis of breast cancer.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: January 22, 2019
    Assignee: BERTIS CO., LTD.
    Inventors: Heon Soo Lee, Hye Seoung Shin, Un-Beom Kang, Dong-Young Noh, Hyeong-Gon Moon
  • Patent number: 10174326
    Abstract: The present invention provides a TLR7 ligand and its use in therapeutic applications. Specifically, the present application provides a RNA oligonucleotide comprising a G:U wobble base pair in the context of a fully double-stranded structure and its use in treating disease such as viral infections, immune disorders and cancer.
    Type: Grant
    Filed: March 17, 2010
    Date of Patent: January 8, 2019
    Assignee: Rheinische Friedrich-Wilhelms-Universität Bonn
    Inventors: Gunther Hartmann, Winfried Barchet, Vera Wimmenauer
  • Patent number: 10166176
    Abstract: Zinc oxide compositions as well as techniques for plasmonic enhancement of absorption in sunscreen applications are provided herein. A method includes selecting one or more metal particles to be used in conjunction with one or more zinc oxide particles in a sunscreen composition, wherein said selecting is based on the plasmon resonance frequency associated with each of the metal particles; and embedding the one or more selected metal particles into each of the one or more zinc oxide particles.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: January 1, 2019
    Assignee: International Business Machines Corporation
    Inventors: Talia S. Gershon, Yun Seog Lee, Ning Li, Devendra Sadana, Teodor K. Todorov
  • Patent number: 10143758
    Abstract: Disclosed herein are compositions and methods of modulating the expression of gene or the production of a protein by transfecting target cells with nucleic acids. The compositions disclosed herein demonstrate a high transfection efficacy and are capable of ameliorating diseases associated with protein or enzyme deficiencies.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: December 4, 2018
    Assignee: Translate Bio, Inc.
    Inventors: Braydon Charles Guild, Frank DeRosa, Michael Heartlein
  • Patent number: 10138213
    Abstract: Provided, in part, is a composition comprising one or more chemical entities of formula I, each of which is a compound of formula I: a pharmaceutically acceptable salt thereof, a solvate thereof, or a solvate of a pharmaceutically acceptable salt thereof, the composition characterized in that greater than a first threshold amount of the total amount of chemical entities of formula I in the composition: are chemical entities of formula I.a, wherein the first threshold amount is 50%; or are chemical entities of formula I.b.1, wherein the first threshold amount is 25%; or are chemical entities of formula I.b.2, wherein the first threshold amount is 25%, wherein the chemical entities of formula I.a, I.b.1, and I.b.2, are described herein, and methods of using such compositions, for example, for the delivery of a polynucleotide in vivo.
    Type: Grant
    Filed: June 24, 2015
    Date of Patent: November 27, 2018
    Assignee: Translate Bio, Inc.
    Inventors: Frank DeRosa, Shrirang Karve, Michael Heartlein
  • Patent number: 10092487
    Abstract: Zinc oxide compositions as well as techniques for plasmonic enhancement of absorption in sunscreen applications are provided herein. A method includes selecting one or more metal particles to be used in conjunction with one or more zinc oxide particles in a sunscreen composition, wherein said selecting is based on the plasmon resonance frequency associated with each of the metal particles; and embedding the one or more selected metal particles into each of the one or more zinc oxide particles.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: October 9, 2018
    Assignee: International Business Machines Corporation
    Inventors: Talia S. Gershon, Yun Seog Lee, Ning Li, Devendra Sadana, Teodor K. Todorov
  • Patent number: 10039702
    Abstract: Provided is a cleansing composition for skin or hair capable of bringing about a good rinse feel and durability of foam and, in regard to hair, imparting finger combability during rinsing as well as softness to hair during rinsing and after towel drying, and further, imparting a sufficient moist feeling also to skin after application. A cleansing composition for skin or hair, comprising the following (A) and (B): (A) an internal olefin sulfonate having 12 or more and 24 or less carbon atoms; and (B) a cationic polymer or an amphoteric polymer.
    Type: Grant
    Filed: September 19, 2013
    Date of Patent: August 7, 2018
    Assignee: KAO CORPORATION
    Inventors: Ryosuke Fujii, Yasuhiro Doi
  • Patent number: 10022457
    Abstract: Methods and compositions to controllably regulate cells at a target site. A quantum dot-targeting agent complex is administered to a patient in need of therapy, and the complex is stimulated using an implanted fiber optic system. In embodiments, the system includes an electrical sensor that detects and monitors electrical activity of the stimulated controllably regulated cells, and relays this information to a controller that can regulate further stimulation.
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: July 17, 2018
    Inventor: Gholam A. Peyman
  • Patent number: 10016467
    Abstract: This invention relates to solid formulations for the oral delivery of live microbial cells which comprise dried viable cells and small amounts of a bile acid binding agent, for example, an anion exchange resin such as cholestyramine. The presence of bile acid binding agents in the formulation significantly increases the survival of the cells in the intestinal tract and facilitates delivery of the viable cells to the intestine.
    Type: Grant
    Filed: January 11, 2010
    Date of Patent: July 10, 2018
    Assignees: Cambridge Enterprise Limited, Prokarium Limited
    Inventors: Alexander Edwards, Nigel Slater
  • Patent number: 9975924
    Abstract: An approach of producing recombinant trimers that mimic native HIV-1 envelope trimers is developed. A recombinant protein forming the recombinant trimers encompasses a recombinant HIV-1 gp140 fused to a tag through a linker at C-terminus of the recombinant HIV-1 gp140. The linker is sufficiently long so that the tag is accessible for binding by a binding molecule bound on a solid matrix. After expressed in a cell, the recombinant protein is secreted into the culture medium and assembles into recombinant trimers therein. The recombinant trimers may be directly purified from the culture medium. Cleaved and uncleaved trimers from different clade viruses are produced.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: May 22, 2018
    Assignee: The Catholic University of America
    Inventors: Venigalla B. Rao, Wadad Alsalmi
  • Patent number: 9962558
    Abstract: Minimally invasive delivery with intercellular and/or intracellular localization of nano- and micro-particle solar cells within and among excitable biological cells to controllably regulate membrane polarization and enhance function of such cells. The cells include retinal and other excitable cells.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: May 8, 2018
    Inventor: Gholam A. Peyman
  • Patent number: 9956425
    Abstract: Methods and compositions to controllably regulate cells at a target site. A quantum dot-targeting agent complex is administered to a patient in need of therapy, and the complex is stimulated using an implanted fiber optic system. In embodiments, the system includes an electrical sensor that detects and monitors electrical activity of the stimulated controllably regulated cells, and relays this information to a controller that can regulate further stimulation.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: May 1, 2018
    Inventor: Gholam A. Peyman
  • Patent number: 9873535
    Abstract: The present invention concerns a composition and method of using non-molybdate corrosion inhibitors in sterilizing and pasteurizing applications. The composition is a blend of one or more components including corrosion inhibitors, surfactants, hydrotropes, polymer dispersants, pH adjusting agents and water. The composition may include two or more of a) alkyl-dicarboxylic acid; b) phosphono-carboxylic acid; c) tri(amino-carboxylic acid); d) anionic polymer dispersant; e) non-ionic surfactant; f) inorganic phosphate; g) phosphonotricarboxylic acid; and h) hydrotrope. Specifically, the composition may comprise sebacic acid, hydroxyphosphonoacetic acid, and 6,6?,6?-(1,3,5-triazine-2,4,6-triyltriimino)tris-hexanoic acid. Optionally, the composition can further comprise a co-polymer of acrylic acid and allyl-2-hydroxy-propyl-sulfonate ether (AA/AHPSE), 2-phosphono-1,2,4-butane-tricarboxylic acid, sodium phosphate monobasic or phosphoric acid, ?-decyl-?-hydroxy-poly(oxy-1,2ethanediyl), and sodium cumenesulfonate.
    Type: Grant
    Filed: June 19, 2012
    Date of Patent: January 23, 2018
    Assignee: Genral Electric Company
    Inventors: Zhendong Liu, Donald A. Meskers, Jr., Peter Scheidel
  • Patent number: 9855199
    Abstract: The present invention relates to a cosmetic basic composition comprising hydroxypropylmethylcellulose (HPMC) modified with C15-C20 alkyl ether groups as thickener, Oleosomes and water, wherein the Oleosomes comprise at least one cosmetically active substance. The invention also relates to the use of the cosmetic basic composition in products of decorative cosmetics, personal care cosmetics and/or skin protection cosmetics.
    Type: Grant
    Filed: July 22, 2015
    Date of Patent: January 2, 2018
    Assignee: Coty Germany GmbH
    Inventors: Lethu Nguyen, Salvatore J. Barone, Ralph Macchio